Top

Published in:

01-06-2013 | Breast Oncology

Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence

Authors: Makoto Ishitobi, MD, Yasuhiro Okumura, MD, Nobuyuki Arima, MD, Atsushi Yoshida, MD, Katsuhiko Nakatsukasa, MD, Takuji Iwase, MD, Tadahiko Shien, MD, Norikazu Masuda, MD, Satoru Tanaka, MD, Masahiko Tanabe, MD, Takehiro Tanaka, MD, Yoshifumi Komoike, MD, Tetsuya Taguchi, MD, Reiki Nishimura, MD, Hideo Inaji, MD

Published in: Annals of Surgical Oncology | Issue 6/2013

Abstract

Background

There is little information about the impact of breast cancer subtype on prognosis after ipsilateral breast tumor recurrence (IBTR).

Methods

One hundred eighty-five patients were classified according to breast cancer subtype, as approximated by estrogen receptor, human epidermal growth factor receptor 2 (HER2), and Ki-67, of IBTR, and we evaluated whether breast cancer subtype was associated with distant recurrence after IBTR.

Results

There was a significant difference in distant disease-free survival (DDFS) after IBTR according to breast cancer subtype defined by a cutoff of the Ki-67 index of 20 % (p = 0.0074, log-rank test). The 5-year DDFS rates for patients with luminal A, luminal B, triple-negative, and HER2 types were 86.3, 57.1, 56.6, and 65.9 %, respectively. In addition, breast cancer subtype was significantly associated with distant recurrence after IBTR on adjustment for various clinicopathologic factors (p = 0.0027, Cox proportional hazards model).

Conclusions

Our study suggests that breast cancer subtype based on immunohistochemical staining predicts the outcomes of patients with IBTR. Further analyses are needed (UMIN-CTR number UMIN000008136).

Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.

Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.PubMedCrossRef

Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.CrossRef

Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer. 2006;106:35–41.PubMedCrossRef

Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27:2466–73.PubMedCrossRef

Whelan T, Clark R, Roberts R, et al. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys. 1994;30:11–6.PubMedCrossRef

Haffty BG, Reiss M, Beinfield M, et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol. 1996;14:52–7.PubMed

Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52.PubMedCrossRef

Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.PubMedCrossRef

10.

Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef

11.

Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.PubMedCrossRef

12.

Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.PubMedCrossRef

13.

Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83.PubMedCrossRef

14.

Millar EK, Graham PH, O’Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;:4701–8.PubMedCrossRef

15.

Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008;26:2373–8.PubMedCrossRef

16.

Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.PubMedCrossRef

17.

Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010;1:747–54.PubMedCrossRef

18.

Panet-Raymond V, Truong PT, Alexander C, et al. Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. Cancer 2011;117:2035–43.PubMedCrossRef

19.

Komoike Y, Akiyama F, Iino Y, et al. Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer. 2005;12:104–11.PubMedCrossRef

20.

Yi M, Buchholz TA, Meric-Bernstam F, et al. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011;253:572–9.PubMedCrossRef

21.

Yoshida T, Takei H, Kurosumi M, et al. True recurrences and new primary tumors have different clinical features in invasive breast cancer patients with ipsilateral breast tumor relapse after breast-conserving treatment. Breast J. 2010;16:127–33.PubMedCrossRef

22.

López-Guerrero JA, Llombart-Cussac A, Noguera R, et al. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int J Cancer. 2006;118:1743–9.PubMedCrossRef

23.

Parikh RR, Housman D, Yang Q, et al. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:1056–63.PubMedCrossRef

24.

McGrath S, Antonucci J, Goldstein N, et al. Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast-conserving therapy: a molecular based clonality evaluation. Am J Clin Oncol. 2010;33:17–22.PubMedCrossRef

25.

Bollet MA, Servant N, Neuvial P, et al. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. J Natl Cancer Inst. 2008;100:48–58.PubMedCrossRef

26.

Montagna E, Bagnardi V, Rotmensz N, et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012;23:324–31.PubMedCrossRef

27.

Ishitobi M, Komoike Y, Nakahara S, et al. Repeat lumpectomy for ipsilateral breast tumor recurrence after breast-conserving treatment. Oncology 2011;81:381–6.PubMedCrossRef

28.

Ishitobi M, Ohsumi S, Inaji H, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the M. D. Anderson Prognostic Index. Cancer. 2012;118(18):4385–93. doi:10.1002/cncr.27377 [Online January 17, 2012].

29.

Mandelblatt JS, Kerner JF, Hadley J, et al. Variations in breast carcinoma treatment in older Medicare beneficiaries: is it black or white. Cancer. 2002;95:1401–14.PubMedCrossRef

30.

Yood MU, Owusu C, Buist DS, et al. Mortality impact of less-than-standard therapy in older breast cancer patients. J Am Coll Surg. 2008;206:66–75.PubMedCrossRef

31.

Chen SL, Martinez SR. The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence. Am J Surg. 2008;196:495–9.PubMedCrossRef

32.

Gentilini O, Botteri E, Veronesi P, et al. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol. 2012;19(12):3771-6. doi:10.1245/s10434-012-2404-5 [Online May 23, 2012].

33.

Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103:1656–64.PubMedCrossRef

34.

de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96:1504–13.PubMedCrossRef

Title: Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence
Authors: Makoto Ishitobi, MD
Yasuhiro Okumura, MD
Nobuyuki Arima, MD
Atsushi Yoshida, MD
Katsuhiko Nakatsukasa, MD
Takuji Iwase, MD
Tadahiko Shien, MD
Norikazu Masuda, MD
Satoru Tanaka, MD
Masahiko Tanabe, MD
Takehiro Tanaka, MD
Yoshifumi Komoike, MD
Tetsuya Taguchi, MD
Reiki Nishimura, MD
Hideo Inaji, MD
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2825-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Breast Cancer Subtype and Distant Recurrence after Ipsilateral Breast Tumor Recurrence

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2013

Postchemoradiation Resected Locally Advanced Esophageal and Gastroesophageal Junction Carcinoma: Long-Term Outcome With or Without Intraoperative Radiotherapy

Factors Associated with Breast MRI Use: A Population-Based Analysis

A Systematic Review and Meta-analysis Comparing the Efficacy and Surgical Outcomes of Total Thyroidectomy Between Harmonic Scalpel Versus Ligasure

Comprehensive Databases: A Cautionary Note

Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer

Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer Registries